Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM) (BEAM)

March 18, 2026 updated by: Wern Ee Tang, National Healthcare Group Polyclinics

Randomised Controlled Trial Of Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting.

The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting.

Researchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

240

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Singaporeans or Singapore Permanent Residents
  2. Patients aged ≥21 to 65 years old
  3. Physician diagnosed asthma for duration of at least 4 weeks
  4. On or will be initiated on Global Initiative for Asthma (GINA) 2025 step 1-3) treatment
  5. No asthma exacerbations* in the preceding 4 weeks before randomisation
  6. Able and willing to attend study appointments approximately every 4-monthly over a 1-year period
  7. Able to provide informed consent
  8. Stable cardiovascular status (i.e. controlled hypertension, no active symptoms of heart disease or arrhythmias) *Exacerbations are defined as worsening of asthma symptoms requiring systemic corticosteroid for 3 or more days, emergency department visit, or hospitalization

Exclusion Criteria:

  1. History of life-threatening asthma requiring intubation or intensive care unit admission
  2. Severe asthma or difficult to treat asthma
  3. Current use of long-term immunosuppression, LTRA receptor antagonist (Montelukast) and Theophylline or long-term oral steroids
  4. Presence of other known causes of eosinophilia besides asthma (e.g. parasitic infection), based on physician's discretion and investigation as per clinical practice and suspicion
  5. Current use of beta-blocking agents including eye-drops
  6. Use of oral, rectal, or parenteral glucocorticoid within 30 days and/or depot parenteral glucocorticoid within 12 weeks prior to recruitment
  7. Known diagnosis of Chronic Obstructive Pulmonary Disease, Interstitial lung disease or bronchiectasis
  8. Any significant disease or disorder (eg. Cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study
  9. Current enrolment in other interventional clinical trial for asthma
  10. Female subjects who are pregnant or planning pregnancy during the study period
  11. Planned travel outside of the country for ≥16 consecutive weeks during the study
  12. Investigator's assessment of poor capability of following study instructions or comply with study procedures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Biomarker-Directed Arm
Asthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed).
Diagnostic test: Biomarker-directed treatment for asthma management
Asthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed).
Other: Control Arm (Usual Care)
Participants in the control arm will receive usual care, this does not involve the use of blood eosinophils
Other: Usual Care
Participants in this arm will receive usual asthma care in primary care that does not involve the use of blood eosinophils

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to first asthma exacerbation requiring hospitalisation
Time Frame: Within 12 months from enrollment
Time to first asthma exacerbation requiring hospitalisation comparing usual care vs biomarker-directed care measured in days.
Within 12 months from enrollment
Number of asthma exacerbations not requiring hospitalisation
Time Frame: From enrollment to 12 months
Number of asthma exacerbations not requiring hospitalisation comparing usual care vs biomarker-directed care measured via counts.
From enrollment to 12 months
Worsening of asthma symptoms
Time Frame: From enrollment to 12 months
Worsening of asthma symptoms based on Asthma Control Test Score (ACT score decrease ≥3 points from baseline) comparing usual care vs biomarker-directed care measured based on scores and percentage of scores.
From enrollment to 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Asthma exacerbations requiring systemic corticosteroids and urgent healthcare visits
Time Frame: From enrollment to 12 months
Asthma exacerbations requiring systemic corticosteroids and urgent healthcare visits (outpatient, ED, admissions) measured via counts.
From enrollment to 12 months
Change in Asthma Quality of Life Questionnaire score
Time Frame: From enrollment to 12 months
Change in asthma quality of life questionnaire (AQLQ) score from baseline measure via score points ranging from 1-7, with higher scores indicating better quality of life.
From enrollment to 12 months
Change in Asthma Control Test score
Time Frame: From enrollment to 12 months
Change in Asthma Control Test (ACT) scores from baseline measure via score points ranging from 5-25, with higher scores indicating better asthma control.
From enrollment to 12 months
Change in Global Initiative for Asthma score
Time Frame: From enrollment to 12 months
Change in Global Initiative for Asthma (GINA) scores from baseline measure via score points ranging from 0-4, with lower scores indicating better asthma control.
From enrollment to 12 months
Changes in Forced Expiratory Volume in 1 second
Time Frame: From enrollment to 12 months
Changes in Forced Expiratory Volume in 1 second (FEV1) from spirometry test, measured in litres, percentages and litres per second. Lower FEV1 value indicates lung obstruction.
From enrollment to 12 months
Changes in Forced Vital Capacity
Time Frame: From enrollment to 12 months
Changes in Forced Vital Capacity (FVC) from spirometry test, measured in litres, percentages and litres per second. Lower FVC value indicates lung obstruction.
From enrollment to 12 months
Changes in Forced Expiratory Volume in 1 second/Forced Vital Capacity Ratio
Time Frame: From enrollment to 12 months
Changes in Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio from spirometry test, measured in litres, percentages and litres per second. FEV1/FVC below 0.70 typically indicates airway obstruction.
From enrollment to 12 months
Changes in Peak Expiratory Flow
Time Frame: From enrollment to 12 months
Changes in Peak Expiratory Flow (PEF) from spirometry test, measured in litres, percentages and litres per second. Higher PEF value indicates good asthma control.
From enrollment to 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Healthcare Group Polyclinics

Collaborators

Singapore General Hospital
National Medical Research Council (NMRC), Singapore

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 3, 2025

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

December 5, 2025

First Submitted That Met QC Criteria

March 18, 2026

First Posted (Actual)

March 20, 2026

Study Record Updates

Last Update Posted (Actual)

March 20, 2026

Last Update Submitted That Met QC Criteria

March 18, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024-4243

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Eosinophil Blood Count

Clinical Trials on Biomarker-directed treatment for asthma management

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe